Skip Ribbon Commands
Skip to main content

LifePearl™

Drug Elutable Microspheres

Description

Because experience matters

Terumo Interventional Oncology Division presents LifePearl, a precise answer to a challenge in interventional oncology. LifePearl are PEG (polyethylene glycol) embolization microspheres that can be loaded with chemotherapeutic agents (such as Doxorubicin, Irinotecan, Idarubicin and Epirubicin).

LifePearl offers:

  • Wide range of drug loading options1
  • Enhanced suspension characteristics2, 4, 5
  • Tight calibration3, 4, 5
  • Syringe presentation

Veloso et al reported results from one of the largest multicentric cohorts of unresecable HCC patients (n=580) treated with LifePearl™ microspheres to date6:
  • Over 4 years Median OS (50.8 months [95% CI 44.7–NE])
  • 60.1% complete response rate exceeding what is reported in previous studies
    7,8,9

Characteristics

​LifePearlTM microspheres are designed to actively absorb drugs into their matrix2

  • 37.5 mg of Doxorubicin per 1 ml of LifePearl® microspheres
  • 5mg of Idarubicin per 1ml of LifePearl® microspheres
  • 25mg of Epirubicin per 1ml of LifePearl® microspheres
  • 50.0 mg of Irinotecan per 1 ml of LifePearl® microspheres


LifePearlTM has a tight calibration which may lead to a more targeted embolisation

​Diameter distribution histogram of doxorubicin-loaded microspheres4

Picture1.png

Diameter distribution histogram of irinotecan-loaded microspheres5

Picture2.png


LifePearlTM offers longer time in suspension than:

  • DC Bead and HepaSphere when loaded with Doxorubicin4
  • DC Bead and Tandem when loaded with Irinotecan5

Longer time in suspension allows smoother embolization procedure without the need for interruption to resuspend the microspheres

​Microsphere type​Doxorubicin loaded
Time in suspension (s)
​Irinotecan loaded
Time in suspension (s)
​LifePearl​357±7392±23​
​DC Bead​185±11154±13
​Tandem​504±12​198±19
​HepaSphere​172±20​N/A


LifePearlTM loaded with Doxorubicin or Irinotecan offers:

  • A steady, continuous and lasting elution over an extended period of time


Doxorubicin elution4

Picture3.png
​​​

Preparation

Video instructions

   ​​
  

Clinical evidence

See all clinical evidence

General specifications

Volume of microspheres2 ml
Volume of PBS4 ml


Comparison of loading times with Irinotecan, Doxorubicin, Idarubicin and Epirubicin1,7

LifePearl sizes​75 mg liquid Doxorubicin per 2 ml of microspheres75 mg powder​ Doxorubicin per 2 ml of microspheres​100 mg Irinotecan solution per 2 ml of microspheres10 mg Idarubicin solution per 2 ml of microspheres​​50 mg Epirubicin solution per 2 ml of microspheres
​100 ± 25 µm​1 hour​30 minutes30 minutes​​30 minutes​​1 hour
​200 ± 50 µm​4 hours​30 minutes​30 minutes​30 minutes​​1 hour
​400 ± 50 µm​6 hours30 minutes​​30 minutes​4 hours​3 hour

Item specifications

LifePearl sizesColourItem reference
100 ± 25 μmBlack8LP2S100
200 ± 50 μmYellow8LP2S200
400 ± 50 μmBlue8LP2S400

Please quote above item reference codes when placing an order.

LifePearl is not available for sale in all countries. This information is provided only in respect to markets where this product is approved or cleared.  LifePearl is cleared in US with indications for embolization of hyper vascular tumors and arteriovenous malformations. LifePearl is not approved in Canada. Please contact your Terumo local sales representative for more information.

Downloads

References

1 LifePearl Instructions for Use (January 2018)
Data on file. Comparison with Terumo's previously commercialized product. Ref LPMCV-004
Data on file. Ref LPBTG-002, LPMCV-003, LPMCV-004. Microvention Inc. Comparison with Terumo's previously commercialized product
Thierry de Baere, et al. An In Vitro Evaluation of Four Types of Drug-Eluting Microspheres Loaded with Doxorubicin. J Vasc Interv Radiol. 2016 Sep;27(9):1425-1431
Philippe L. Pereira, et al. An in-vitro evaluation of three types of drug-eluting microspheres loaded with irinotecan Anti-Cancer Drugs: October 2016 - Volume 27 - Issue 9 - p 873–878
Veloso Gomes P et al Cardiovasc Intervent Radiol 2023 46, 436–446
Meyer T, et al. Lancet Gastroenterol Hepatol. 2017
Kudo M, et al. Gut. 2020

9 Lencioni R, et al. J Hepatology. 2016

10 Data on file. Ref TR14-286 Microvention Inc. Comparison with Terumo's previously commercialized product​

Do you need more info about this product?

Our sales representatives are here for you.

Contact us
Send us a message
I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*
I wish to receive information and marketing updates from Terumo.
* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Didn't find your product?

Consult our products in our Product Index

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public


For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.